Reversibility effects of ipratropium bromide and terbutalin sulphate in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 72s Year: 2001
Salbutamol or ipratropium bromide: does gender and age influence the response to drugs? Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases Year: 2021
Pulmonary function and bronchodilator response to albuterol, ipratropium bromide and association of albuterol and ipratropium bromide in children with cystic fibrosis (CF) Source: Eur Respir J 2003; 22: Suppl. 45, 229s Year: 2003
Airway tone during exercise in healthy subjects: effects of salbutamol and ipratropium bromide Source: Eur Respir J 2003; 22: Suppl. 45, 89s Year: 2003
Cardiopulmonary effects of inhaled ipratropium bromide and its combination with fenoterol in patients with bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 58s Year: 2002
Effect of patient age on response to nebulised salbutamol or ipratropium bromide Source: Annual Congress 2012 - Going with the flow: assessment and evaluation of airway function and its role in patient management Year: 2012
Ipratropium bromide pre-treatment influences recovery after methacholine induced bronchospasm Source: Eur Respir J 2002; 20: Suppl. 38, 505s Year: 2002
Bronchodilation test: Salbutamol or Ipratropium Bromide? Source: Virtual Congress 2020 – Clinical and functional evaluation of asthmatics Year: 2020
Monitoring of nasal permeability during the treatmrnt of patients with overlap syndrome with combined broncholytic drug (ipratropium bromide + salbutamol) Source: Eur Respir J 2001; 18: Suppl. 33, 216s Year: 2001
A comparison of early bronchodilating responses of Salbutamol, Ipratropium bromide, and the combination of Ipratropium bromide-Salbutamol in stable patients with COPD or asthma Source: Eur Respir J 2002; 20: Suppl. 38, 246s Year: 2002
Bronchodilator/bronchoprotective effects of aclidinium bromide, a novel long-acting anticholinergic: a phase I study Source: Annual Congress 2007 - Mechanisms and new treatments of COPD Year: 2007
How long should tiotropium bromide be suspended before methacholine challenge? Source: Eur Respir J 2006; 28: Suppl. 50, 218s Year: 2006
Sleep architecture in COPD patients during salmeterol versus ipratropium bromide treatment Source: Eur Respir J 2004; 24: Suppl. 48, 113s Year: 2004
Comparison of nebulized ipratropium bromide with salbutamol versus salbutamol alone in acute asthma exacerbation in children Source: Eur Respir J 2004; 24: Suppl. 48, 167s Year: 2004
Influence of higher than conventional doses of salbutamol or ipratropium bromide on bronchodilation induced by a regular treatment with tiotropium in patients suffering from stable COPD Source: Eur Respir J 2007; 30: Suppl. 51, 356s Year: 2007
Improved delivery of fenoterol plus ipratropium bromide using Respimat(R) compared with a conventional metered dose inhaler Source: Eur Respir J 2001; 17: 225-232 Year: 2001
The efficacy of long-acting anticholinergic agent, tiotropium bromide on dynamic hyperinflation in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006
Is there any point in treatment of patients with chronic obstructive pulmonary diseases with salmeterol and ipratropium bromide, alone and in combination? Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002
Different inhalation volumes do not impact on the aerodynamics of aclidinium bromide delivered using the Genuair® inhaler Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Interaction between tiotropium bromide and olodaterol in small human airways Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017